Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

sacituzumab tirumotecan (MK-2870)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Merck (MSD), Sichuan Kelun Pharma

Drug class:

Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate

Related drugs:

‹

irinotecan liposomal (0)

topotecan episcleral (0)

hIMB1636-MMAE (1)

anti TROP-2 antibody therapeutic (0)

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

sacituzumab govitecan-hziy (17)

HRA00129-C004 (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

hIMB1636-MMAE (1)

anti TROP-2 antibody therapeutic (0)

›

EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	MK-2870 Sensitive: C2 – Inclusion Criteria MK-2870 Sensitive : C2	MK-2870 Sensitive: C2 – Inclusion Criteria MK-2870 Sensitive : C2
TROP2 overexpression	Triple Negative Breast Cancer	TROP2 overexpression	Triple Negative Breast Cancer	MK-2870 Sensitive: C3 – Early Trials MK-2870 Sensitive : C3	MK-2870 Sensitive: C3 – Early Trials MK-2870 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	MK-2870 Sensitive: C3 – Early Trials MK-2870 Sensitive : C3	MK-2870 Sensitive: C3 – Early Trials MK-2870 Sensitive : C3